The Brain Care Score is a tool encompassing 12 modifiable risk factors that may help measure brain health and identify stroke risk.

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

The Food and Drug Administration has approved Nereus (tradipitant) for the prevention of vomiting induced by motion in adults.

Circadian rhythms that are weaker or more fragmented appear to be associated with increased risk for dementia.

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Sports injuries are not more frequent during menstruation, but injuries sustained during menstruation have a significantly higher burden.

Prevention, screening, and vaccination are vital for managing infection risk during pregnancy due to altered maternal immunity.

Topline data were announced from a phase 3 trial evaluating valbenazine in pediatric and adult patients with dyskinetic cerebral palsy.

Carotid stenosis severity serves as a predictor for cognitive impairment independent of white matter lesions and traditional vascular risk factors.